Prostatic Neoplasms: Clinical Trials

949 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

949 completed. 949 Phase 2, 169 Phase 1, 32 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2949Completed 949
Phase 1169Completed 169
Phase 332Completed 32

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 949 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy
0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery, 0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery, 0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery - Prostate Cancer
Phase 2CompletedZhu Yinjie182026-03-202026-09-30
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
Pub2Post - Prostate Cancer (Adenocarcinoma), Bladder Cancer
Phase 2CompletedUniversity of Southern California1202025-01-162026-05-06
Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial
Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate - Prostate Cancer
Phase 1 / Phase 2CompletedUniversity of Washington3502025-01-092026-02-17
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
64Cu-SAR-bisPSMA - Prostate Cancer (Post Prostatectomy)
Phase 2CompletedSt Vincent's Hospital, Sydney502024-11-212026-08-14
68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
68Ga-P16-093 - Prostate Cancer (Adenocarcinoma)
Phase 2CompletedFirst Affiliated Hospital of Fujian Medical University822024-10-012026-10-23
CYTALUX™for the Intraoperative Imaging of Prostate Cancer
Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery - Prostate Cancer
Phase 2CompletedIndiana University92024-09-192026-06-01
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
68Ga-NYM032 injection - Prostate Cancer
Phase 1 / Phase 2CompletedNorroy Bioscience Co., LTD202024-06-042025-05-21
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Debio 4228 - Prostate Cancer
Phase 2CompletedDebiopharm International SA552024-05-232026-08-24
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Phase 2CompletedPedro Barata, MD, MSc132024-05-162025-05-29
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy
NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer
Phase 1 / Phase 2CompletedUniversity College, London212024-05-152025-01-10
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Biopsy, Biospecimen Collection, Computed Tomography - Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2CompletedMayo Clinic72024-03-082026-06-09
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms
Phase 2CompletedMacroGenics1542023-09-282026-05-22
ArtemiCoffee in Patients With Rising PSA
ArtemiCoffee - Prostate Cancer
Phase 2CompletedZin W Myint202023-08-112026-08-11
IS-002 Phase 2 Prostate Cancer Study
Administration of IS-002, Firefly fluorescent imaging, robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection - Prostate Cancer
Phase 2CompletedIntuitive Surgical592023-06-162025-09-04
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor
Phase 1 / Phase 2CompletedSensei Biotherapeutics, Inc.982023-05-312026-09-02
EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.
HIFU hemi-ablation combined with ADT. - Prostate Cancer, Androgen Deprivation Therapy
Phase 2CompletedInstitut Mutualiste Montsouris192023-03-072026-10-02
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor
Phase 1 / Phase 2CompletedKineta Inc.402023-03-032026-10-05
Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence
Propranolol - Prostate Cancer
Phase 2CompletedOslo University Hospital402023-01-022024-05-29
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
64Cu-PSMA I&T - Metastasis From Malignant Tumor of Prostate (Disorder)
Phase 2CompletedCurium US LLC262022-12-052025-01-24
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
177Lu-DOTA-TLX591 - Prostate Cancer
Phase 2CompletedTelix Pharmaceuticals (Innovations) Pty Limited52022-08-302024-12-19

Showing 20 of 949. Sign in to see all of them.

Narrower conditions

Neoplasms (50)  ·  Neoplasm Metastasis (46)  ·  Breast Neoplasms (29)  ·  Carcinoma, Non-Small-Cell Lung (18)  ·  Lung Neoplasms (17)  ·  Ovarian Neoplasms (16)  ·  Urinary Bladder Neoplasms (16)  ·  Colorectal Neoplasms (14)  ·  Melanoma (12)  ·  Colonic Neoplasms (11)  ·  Uterine Cervical Neoplasms (11)  ·  Esophageal Neoplasms (10)  ·  Pancreatic Neoplasms (10)  ·  Kidney Neoplasms (8)

Broader conditions

Genital Diseases (947)  ·  Urogenital Diseases (947)  ·  Genital Diseases, Male (946)  ·  Neoplasms by Site (945)  ·  Male Urogenital Diseases (943)  ·  Genital Neoplasms, Male (942)  ·  Urogenital Neoplasms (942)  ·  Prostatic Diseases (941)  ·  Neoplasms (899)  ·  Pathological Conditions, Signs and Symptoms (77)  ·  Pathologic Processes (62)  ·  Neoplastic Processes (49)  ·  Female Urogenital Diseases (42)  ·  Female Urogenital Diseases and Pregnancy Complications (42)  ·  Neoplasms by Histologic Type (37)

Interventions

Docetaxel (102)  ·  Prednisone (85)  ·  Leuprolide (49)  ·  Abiraterone Acetate (48)  ·  enzalutamide (46)  ·  bicalutamide (38)  ·  Goserelin (36)  ·  Radiotherapy (27)  ·  Estramustine (23)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (21)  ·  gallium 68 PSMA-11 (19)  ·  abiraterone (17)  ·  Carboplatin (16)  ·  Magnetic Resonance Spectroscopy (15)  ·  apalutamide (15)

Sponsors

National Cancer Institute (NCI) (77)  ·  Memorial Sloan Kettering Cancer Center (30)  ·  M.D. Anderson Cancer Center (22)  ·  University Health Network, Toronto (22)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18)  ·  Dana-Farber Cancer Institute (17)  ·  Alliance for Clinical Trials in Oncology (14)  ·  University of Washington (14)  ·  AstraZeneca (12)  ·  Ferring Pharmaceuticals (12)  ·  Barbara Ann Karmanos Cancer Institute (11)  ·  University of California, San Francisco (11)  ·  Astellas Pharma Inc (10)  ·  Bayer (10)  ·  Mayo Clinic (10)

Countries

United States (671)  ·  Canada (108)  ·  United Kingdom (62)  ·  France (54)  ·  Belgium (33)  ·  Germany (33)  ·  Italy (33)  ·  Spain (30)  ·  Netherlands (26)  ·  Australia (19)  ·  Denmark (18)  ·  Finland (17)  ·  Czechia (15)  ·  Russia (15)  ·  Sweden (14)

Top investigators

Mary-Ellen Taplin, MD (10)  ·  Michael Morris, MD (7)  ·  Ravi A Madan, M.D. (7)  ·  Chadi Nabhan, MD (5)  ·  David C. Smith, MD (5)  ·  Christopher Logothetis, MD (4)  ·  David M Schuster, MD (4)

Results publications

PMID 24722180, PMID 25712310, PMID 18777528, PMID 19455472, PMID 21106711, PMID 21802835, PMID 22894553, PMID 23533230, PMID 24510426, PMID 24772219, PMID 24974051, PMID 25475068, PMID 25614256, PMID 25687533, PMID 25786708, PMID 25963190, PMID 26659347, PMID 30189902, PMID 32994091, PMID 33270906, PMID 33465252, PMID 34529005, PMID 35027313, PMID 36001857, PMID 37058234, PMID 37482512, PMID 37496366, PMID 39074346, PMID 41044356, PMID 42186347, PMID 10661346, PMID 11106233, PMID 11586207, PMID 11828001, PMID 11839651, PMID 11905923, PMID 12142053, PMID 12506177, PMID 12610188, PMID 12627508, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14669278, PMID 14727242, PMID 14871968, PMID 14967428, PMID 15054447, PMID 15139054, PMID 15169798

NIH funding

U10CA031946 (9), P30CA022453 (8), 2017 (7), P30CA016672 (6), 2016 (5), P30CA015704 (5), P30CA043703 (5), U10CA021115 (5), U10CA032102 (5), 2008 (4), N01CM62201 (4), N01CM62206 (4), P30CA015083 (4), P30CA023074 (4), U01CA062491 (4)